



Janssen Pharmaceuticals to Invest USD500 Million in China to Develop Pulmonary Disease Drugs

YICAI GLOBAL X

DATE: MAY 19 2017 / SOURCE: YICAI



Janssen Pharmaceuticals to Invest USD500 Million in China to Develop Pulmonary Disease Drugs

(Yicai Global) May 19 -- Janssen Pharmaceuticals Inc. will invest more than USD500 million in China to develop medicines to treat pulmonary disease, which is rampant in the country.

Eventual production will first be marketed in China before extending to the whole world, said William N. Hait, global head of Janssen's research and development department.

Janssen, a subsidiary of the US Johnson & Johnson [NYSE:JNJ] pharmaceutical company, plans to market more than 10 new drugs or apply for approvals from regulatory institutions, and will expand its line of over 50 existing products between 2017-2021. The company will also promote its

RELATED

China Helps Saudi Arabia Explore Uranium Ore Amid Alternative Energy Push

XU WEI / DEC 19 2017

China's Nio to Recall More Than 245,000 EVs Over Software Issue

GE HUI / FEB 10 2026

Chinese Air Con Firms Focus on Branding, Low-Tariff Plants in SE Asia to Hike Exports

WANG ZHEN / MAR 26 2024

Shanghai to Keep Promoting IC, Biomedicine, AI Industries, Mayor Says

JIN YEZI / JAN 24 2024

China's Internet Giant NetEase Invests in Developer of Pokemon GO in USD200 Mln B-Round Funding

CHEN JUAN / NOV 27 2017

Accord BioPharma, Inc.
Exhibit 1060
Accord v. Janssen
IPR2026-00256, -00257, -00258, -00259
Ex. 1060-001

sustainable growth by taking advantage of its core product mix, innovation mode, and Swiss Actelion Pharmaceuticals Ltd., which Janssen will soon acquire. The US Food and Drug Administration has approved 11 of the company's new molecular medicines since 2011, Economic Information Daily reported.

As the company's Chinese market rapidly develops, one focus of Johnson & Johnson's global strategy is to continue to invest in China, said Alex Gorsky, Johnson & Johnson's global board chairman and chief executive. The pharmaceutical department will be key to the company's innovation and growth, helping it to realize steady, consistent and sustainable development.

Follow Yicai Global on    

Keywords: Janssen Pharmaceuticals, Pulmonary Disease

 Report

[HOME](#) [ECONOMY](#) [BUSINESS](#) [TECH](#) [AUTO](#) [OPINION](#)



[YICAI GLOBAL APP](#) | [ABOUT US](#) | [CONTACT US](#) | [CAREER](#) | [PRIVACY POLICY](#)

© 2017 - 2018 Yicai Global, Yicai Media Group. All Rights Reserved.

Report harmful issues: 86-4006060101-6 互联网新闻信息服务许可证:31120180001

ICP备案(增值电信业务经营许可证 沪B2-20050348号 互联网视听节目服务(AVSP):沪备2014002 沪ICP备11023243号-25 沪公网安备31010602000015号)